AMCR vs BURL

AMCR's deterministic health score is stable with a Piotroski F-Score of 6/9, indicating moderate financial strength, though the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($29.87) and intrinsic value ($10.92), supported by a high forward P/E of 9.96 despite a trailing P/E of 28.38, suggesting optimism around earnings recovery. While revenue growth is robust (71.3% YoY), earnings growth is negative (-14.4% YoY), and the dividend payout ratio is dangerously high at 169.44%, raising sustainability concerns. Analysts are strongly bullish with a $55.01 target price, but weak recent earnings beats (1 of last 4) and bearish technicals (0/100) create conflicting signals.

BURL's Piotroski F-Score of 6/9 indicates stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades significantly above its Graham Number of $69.35 at $297.96, reflecting high growth expectations, while its ROE of 41.92% and strong earnings growth signal operational efficiency. However, a high P/E of 34.25, elevated Debt/Equity of 3.90, and bearish insider activity temper optimism. Analysts recommend 'buy' with a target of $339.29, suggesting upside potential despite valuation concerns.